Home
Live Updates
Frontline Nivolumab Plus Chemotherapy Boosts OS and PFS in Metastatic Urothelial Carcinoma : comparemela.com
Frontline Nivolumab Plus Chemotherapy Boosts OS and PFS in Metastatic Urothelial Carcinoma
Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma.
Related Keywords
Netherlands ,
Amsterdam ,
Noord Holland ,
Michiels Van ,
,
Netherlands Cancer Institute ,
Concurrent Frontline Nivolumab And Gemcitabine Cisplatin ,
Urothelial Carcinoma ,
Checkmate 901 Study ,
Nct03036098 ,
Michiels Van Der Heijden ,
D ,
Phd ,
comparemela.com © 2020. All Rights Reserved.